Newron Pharmaceuticals S.p.A. | Finanzwire

Basculer en Français

9529	Companies
187436	Keywords
119464	Articles
100186	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

BRIEF

published on 12/08/2025 at 07:05, 7 days 10 hours ago

Newron Launches US Phase III Study on Evenamide for Schizophrenia

Clinical Trial Schizophrenia Newron Pharmaceuticals Evenamide Phase III Study
PRESS RELEASE

published on 12/08/2025 at 07:00, 7 days 10 hours ago

Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates ENIGMA-TRS 2 Phase III global clinical study in US for treatment-resistant schizophrenia with evenamide as add-on therapy. Expecting results by Q4 2026

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS 2
BRIEF

published on 10/02/2025 at 07:05, 2 months 13 days ago

Newron Pharmaceuticals Highlights Evenamide at ECNP Congress 2025

Clinical Trial Schizophrenia Newron Pharmaceuticals Evenamide ECNP Congress
PRESS RELEASE

published on 10/02/2025 at 07:00, 2 months 13 days ago

Newron to present new analyses from and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 38th ECNP Congress 2025
Newron Pharmaceuticals to present new analyses and updates on evenamide as treatment for schizophrenia at the 38th ECNP Congress 2025

Clinical Program Schizophrenia Newron Pharmaceuticals Evenamide ECNP Congress
BRIEF

published on 09/16/2025 at 07:05, 2 months 29 days ago

Newron Pharmaceuticals Unveils H1 2025 Results and Strategic Advancements

Strategic Partnerships Clinical Trials Newron Pharmaceuticals Evenamide Schizophrenia Treatment
PRESS RELEASE

published on 09/16/2025 at 07:00, 2 months 29 days ago

Newron presents H1 2025 results and provides business update
Newron Pharmaceuticals S.p.A. presents H1 2025 financial results and business update, focusing on evenamide therapy for treatment-resistant schizophrenia patients and strategic partnerships

Business Update Newron Pharmaceuticals Schizophrenia Treatment H1 2025 Results Evenamide Therapy
BRIEF

published on 09/05/2025 at 07:05, 3 months 10 days ago

Newron Pharmaceuticals to Reveal Evenamide Insights at 2025 WCBP

Newron Pharmaceuticals Evenamide Schizophrenia Treatment Clinical Trial Updates Glutamate Modulation
PRESS RELEASE

published on 09/05/2025 at 07:00, 3 months 10 days ago

Newron to present data and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP)
Newron Pharmaceuticals to present data on evenamide as add-on treatment for schizophrenia at 2025 WCBP. Focus on efficacy, safety, and mechanism of action. Landmark studies showcased

Clinical Program Schizophrenia Newron Pharmaceuticals Evenamide WCBP
BRIEF

published on 08/12/2025 at 07:05, 4 months 3 days ago

Newron Initiates Phase III ENIGMA-TRS Study for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals Evenamide Schizophrenia Treatment Phase III Study TRS Therapy
PRESS RELEASE

published on 08/12/2025 at 07:00, 4 months 3 days ago

Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates Phase III ENIGMA-TRS program with evenamide as add-on therapy for treatment-resistant schizophrenia patients, targeting TRS population

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS Program

1 2 ... 6

Accesswire

Published on 12/15/2025 at 16:35, 1 hour ago

Stillwater Critical Minerals Announces Upsize of Bought Deal LIFE Private Placement for Gross Proceeds of C$15 Million
Published on 12/15/2025 at 15:00, 2 hours 35 minutes ago

Kingfisher Reports Annual General Meeting Voting Results
Published on 12/15/2025 at 15:00, 2 hours 35 minutes ago

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Published on 12/15/2025 at 14:30, 3 hours 5 minutes ago

Unusual Machines Congratulates Customers Selected for the Army's PBAS Tranche 1.1, Including Envision Technology and Strategic Logix
Published on 12/15/2025 at 14:00, 3 hours 35 minutes ago

Dateline Delivers Further High-Grade Intercepts from North Pipe at Colosseum

View all ACCESSWIRE

EQS Group

Published on 12/15/2025 at 17:15, 19 minutes ago

His Highness Sheikh Mansour bin Zayed Al Nahyan Launches "Al Khail Square" at Abu Dhabi Equestrian Club
Published on 12/15/2025 at 17:05, 29 minutes ago

Gensyn Launches $AI Token Sale on Sonar
Published on 12/15/2025 at 16:42, 53 minutes ago

EQS-Adhoc: Vitruvia Medical AG: successfull capital increase and strengthening of the financial structure
Published on 12/15/2025 at 16:08, 1 hour 27 minutes ago

Conversion of The Platform Group AG into a KGaA completed as planned
Published on 12/15/2025 at 15:50, 1 hour 44 minutes ago

Original-Research: Cabka N.V. (von First Berlin Equity Research GmbH): Kaufen

Les Echos

Published on 12/15/2025 at 11:50, 5 hours 44 minutes ago

Statement about the number of shares composing the share capital and the number of voting rights as of November 30, 2025
Published on 12/12/2025 at 18:00, 2 days 23 hours ago

Disclosure of trading in own shares between November 24th and November 28th, 2025
Published on 12/12/2025 at 09:15, 3 days 8 hours ago

CHANGE IN THE SHARE CAPITAL
Published on 12/11/2025 at 19:23, 3 days 22 hours ago

Eiffage is joining the CAC 40 index
Published on 12/11/2025 at 08:30, 4 days 9 hours ago

Edenred and Daimler Truck join forces to accelerate the rollout of charging infrastructure for electric trucks in Europe

View all LES ECHOS COMFI WIRE